Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Daniel Hell

97 indexed publications match this author name.

ORCID: Not found in stored metadata
OpenAlex: https://openalex.org/A5083967444

Author watchlist

Create a confirmed email alert for new publications matching this author.

Topics

Depression 35 Safety 33 Clinical Trial 27 Receptor Pharmacology 27 Mechanism of Action 25 Review Article 22 Aging 16 Addiction 16 Brain Imaging 15 Observational Study 15 Treatment-Resistant Depression 14 Pharmacology 13

Journals

PsyArXiv 10 Psychopharmacology 4 Journal of psychoactive drugs 4 Journal of affective disorders 3 Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 3 Neuroscience Applied 3 The International journal on drug policy 3 Frontiers in psychiatry 3

Publication history

Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis.Journal of pain and symptom management · 2026-08-03 Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanismsBehavioural Pharmacology · 2026-08-01 The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisJournal of Affective Disorders · 2026-08-01 The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancerBMC Medicine · 2026-07-06 Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic CircuitsHuman Brain Mapping · 2026-07-01 Provider perspectives on challenges in treatment during psychedelic therapy.Psychopharmacology · 2026-07-01 A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-06-08 U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.Rand health quarterly · 2026-06-01 0408 Insomnia Severity Differences by Psilocybin, LSD, and DMT Use Status Among Young Adult Daily Cannabis Consumers in the Herbal Heart StudySLEEPJ · 2026-05-08 Neural correlates of insight on psilocybin: a within-subjects, healthy volunteer studyJoCN Forum · 2026-05-08 Evaluating the evidence for repressed memory recovery in psychedelic contextsPsychopharmacology · 2026-04-28 Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study ProtocolPsychoactives · 2026-04-13 Observing the mind under psychedelics: conceptual metaphors used following four once-weekly macrodoses of psilocybinPhilosophical Psychology · 2026-04-10 Psilocybin microdosing in the United States: Insights from a nationally representative surveyAddiction · 2026-03-08 Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.Psychedelic medicine (New Rochelle, N.Y.) · 2026-03-01 Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia's clinical landscape.The Australian and New Zealand journal of psychiatry · 2026-02-01 Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].Journal of affective disorders · 2026-01-15 From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care.Translational behavioral medicine · 2026-01-07 The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.American journal of psychotherapy · 2025-12-15 Questioning the recovery of dissociated traumatic memories under psilocybin: comment on "Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa".Journal of eating disorders · 2025-12-04 Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term OutcomesBerkeley Scientific Journal · 2025-11-12 Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.Journal of psychoactive drugs · 2025-11-10 CNSC-36. PSILOCYBIN INDUCES SUSTAINED GLIOMA GROWTH THROUGH SEROTONERGIC AND TRKB PATHWAYSNeuro-Oncology · 2025-11-01 Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.Schizophrenia bulletin · 2025-10-06 Novel perspectives for glutamatergic strategies, psychedelics and antipsychotic augmentation in Treatment Resistant Depression: A narrative reviewClinical Neuropsychopharmacology and Addiction · 2025-09-24 Psilocybin biosynthesis enhancement through gene source optimization.Metabolic engineering · 2025-09-01 551. PSYCHEDELICS AND OCD: TRANSLATIONAL APPROACHESThe International Journal of Neuropsychopharmacology · 2025-07-31 Visual Hallucinations in Serotonergic Psychedelics and Lewy Body DiseasesPsyArXiv · 2025-07-15 Visual Hallucinations in Serotonergic Psychedelics and Lewy Body DiseasesPsyArXiv · 2025-07-15 We need to talk about shrooms.Nordisk alkohol- & narkotikatidskrift: NAT · 2025-05-21 Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2025-05-01 Visual Hallucinations in Serotonergic Psychedelics and Lewy Body DiseasesPsyArXiv · 2025-03-29 Vermont Primary Care Provider Perspectives on Psychedelics - A Cross-Sectional Study.Journal of psychoactive drugs · 2025-03-05 Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.The Journal of clinical psychiatry · 2025-03-03 The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.Journal of affective disorders · 2025-03-01 Visual Hallucinations in Serotonergic Psychedelics and Lewy Body DiseasesPsyArXiv · 2025-02-13 Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners.The Journal of clinical psychiatry · 2025-02-05 Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder.Psychedelics · 2025-01-01 Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.Therapeutic advances in psychopharmacology · 2025-01-01 Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need.Current psychiatry reports · 2024-12-01 Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuitsbioRxiv · 2024-11-07 Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.EClinicalMedicine · 2024-10-01 Psilocybin-assisted therapy and HIV-related shame.Scientific reports · 2024-08-02 Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.Psychopharmacology · 2024-08-01 Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reportsJournal of Psychedelic Studies · 2024-07-17 Prevalence of Psilocybin and Cannabis Concurrent Use During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health StudyDrug and Alcohol Dependence · 2024-07-01 High Blood Pressure Among Psilocybin and Cannabis Consumers During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health StudyDrug and Alcohol Dependence · 2024-07-01 Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectanciesPsyArXiv · 2024-06-10 Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectanciesPsyArXiv · 2024-06-10 Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.bioRxiv: the preprint server for biology · 2024-05-15 Do undergraduates’ views of psychedelics relate to the context for psychedelic use?PsyArXiv · 2024-04-24 Do undergraduates’ views of psychedelics relate to the context for psychedelic use?PsyArXiv · 2024-04-24 Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.Med (New York, N.Y.) · 2024-03-08 Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2024-03-01 Psilocybin vs Escitalopram for depression: 6-month follow-upNeuroscience Applied · 2024-01-01 Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.Psychological medicine · 2024-01-01 IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.Pharmacological research · 2024-01-01 Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.Journal of psychoactive drugs · 2024-01-01 Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities.Biotechnology progress · 2024-01-01 Extended difficulties following the use of psychedelic drugs: A mixed methods studyPLoS ONE · 2023-10-23 Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.Journal of psychiatric research · 2023-05-01 A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapymedRxiv · 2023-04-19 Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.Journal of affective disorders · 2023-04-14 347. Changes in Resting State Functional Connectivity After Psilocybin for Body Dysmorphic DisorderBiological Psychiatry · 2023-04-10 Liminal spaces, seasonal faces: Challenging drug market assumptions via an exploration of naturally occurring magic mushroom markets in rural Kent.The International journal on drug policy · 2023-04-01 Therapeutic effect of psilocybin in addiction: A systematic review.Frontiers in psychiatry · 2023-01-01 Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.Frontiers in psychiatry · 2023-01-01 Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.The New England journal of medicine · 2022-11-03 Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States.The International journal on drug policy · 2022-10-01 Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-30 Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-30 Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.Psychopharmacology · 2022-06-01 Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon.Cureus · 2022-05-01 The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trialNeuroscience Applied · 2022-01-01 The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trialNeuroscience Applied · 2022-01-01 Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity.Frontiers in psychiatry · 2022-01-01 Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.PloS one · 2022-01-01 Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.The International journal on drug policy · 2021-12-01 Psychedelic Drugs for Mental Disorders and Human Potential: Placebo or PanaceaPsychiatric News · 2021-11-29 Trial of Psilocybin versus Escitalopram for Depression.The New England journal of medicine · 2021-04-15 Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.The Journal of neuroscience: the official journal of the Society for Neuroscience · 2021-02-03 Chemical Composition of Traditional and Analog Ayahuasca.Journal of psychoactive drugs · 2021-01-01 Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.Frontiers in pharmacology · 2021-01-01 Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.EClinicalMedicine · 2020-10-01 Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings.Proceedings of the National Academy of Sciences of the United States of America · 2020-02-04 Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder.Journal of experimental pharmacology · 2020-01-01 T137. Psilocybin-Assisted Group Therapy for Demoralization in Long-Term AIDS SurvivorsBiological Psychiatry · 2019-04-30 Psychedelic use and intimate partner violence: The role of emotion regulation.Journal of psychopharmacology (Oxford, England) · 2018-07-01 Psilocybin for treating substance use disorders?Expert review of neurotherapeutics · 2017-02-01 Homological scaffolds of brain functional networks.Journal of the Royal Society, Interface · 2014-12-06 The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.Frontiers in human neuroscience · 2014-01-01 Effects of the hallucinogenic 5-HT2A agonist psilocybin on object completion in humansInternational Journal of Psychophysiology · 2008-07-17 Liquid chromatography-tandem mass spectrometry method for the simultaneous analysis of multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid, and metabolites, in urine.Journal of analytical toxicology · 2007-10-01 Effects of psilocybin on time perception and temporal control of behaviour in humans.Queensland's institutional digital repository (The University of Queensland) · 2006-05-18 Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2005-06-01 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 1999-05-01 Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.Neuroreport · 1998-12-01

Author directory